The Clinical Application of Tumor Reversion: A Phase I study of sertraline (Zoloft) in combination with timed-sequential cytosine arabinoside (ara-C) in adults with relapsed and refractory acute myeloid leukemia (AML)
Study of sertraline (Zoloft) with ara-C in combination in patients with acute myeloid leukemia (AML)
Sponsor: Internal
Enrolling: Male and Female Patients
IRB Number: AAAQ8444
U.S. Govt. ID: NCT02891278
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of the study is to evaluate the safety, tolerability (the effect of the drug on your body), pharmacokinetics (the effect of your body on the drug) and maximum tolerated dose of sertraline in combination with cytosine arabinoside (ara-C, cytarabine) when given to patients with treatment-resistant myeloid leukemia. In addition, the effect of the drug on your cancer and so-called biomarkers (markers of biological activities in your body), will be determined in blood and bone marrow. Another purpose of the study is what effects (both good and bad) it has on you and your cancer.
This study is closed
Investigator
Daniel Lee, MD
Do You Qualify?
Are between 18 and 70 years of age? Yes No
Have you been diagnosed with relapsed AML? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162